Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients.
作者信息
Lochmüller Hanns, Evans David, Farwell Wildon, Finkel Richard, Goemans Nathalie, de Lemus Mencia, Matyushenko Vitaliy, Muntoni Francesco, Ouillade Marie-Christine, Schwersenz Inge, Wilson Petra
机构信息
Department of Neuropediatrics and Muscle Disorders, Medical Center - University ofFreiburg, Faculty of Medicine, Freiburg, Germany.
Data Science - Personalized HealthCare, F. Hoffmann-La Roche, Basel, Switzerland.
出版信息
J Neuromuscul Dis. 2018;5(2):131-133. doi: 10.3233/JND-180325.
Abstract
摘要
相似文献
1
Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients.立场声明：脊髓性肌萎缩症临床研究数据的共享以加速研究并改善患者预后。
J Neuromuscul Dis. 2018;5(2):131-133. doi: 10.3233/JND-180325.
2
Clinical outcome measures in spinal muscular atrophy.脊髓性肌萎缩症的临床结局指标
J Child Neurol. 2009 Aug;24(8):968-78. doi: 10.1177/0883073809332702. Epub 2009 Jun 9.
3
Spinal Muscular Atrophy Type I: Is It Ethical to Standardize Supportive Care Intervention in Clinical Trials?脊髓性肌萎缩症I型：在临床试验中规范支持性护理干预是否符合伦理道德？
J Child Neurol. 2017 Feb;32(2):155-160. doi: 10.1177/0883073816671236. Epub 2016 Oct 22.
4
The Neurobiology of Disease in Children Conference.
J Child Neurol. 2007 Aug;22(8):923-5. doi: 10.1177/0883073807305663.
5
Spinal muscular atrophy-1 and gastrostomy.
J Paediatr Child Health. 2014 Jul;50(7):575-6. doi: 10.1111/jpc.12665.
6
Recommendations for the diagnosis and management of typical childhood spinal muscular atrophy.儿童脊髓性肌萎缩症的诊断和管理建议。
Rev Neurol (Paris). 2012 Dec;168(12):902-9. doi: 10.1016/j.neurol.2012.07.020. Epub 2012 Oct 26.
7
The Experience of Families With Children With Spinal Muscular Atrophy Type I Across Health Care Systems.患有I型脊髓性肌萎缩症儿童的家庭在不同医疗保健系统中的经历。
J Child Neurol. 2017 Oct;32(11):917-923. doi: 10.1177/0883073817716853. Epub 2017 Jul 3.
8
Interview with Jill Jarecki, PhD.对吉尔·亚雷茨基博士的采访。
Assay Drug Dev Technol. 2014 Aug;12(6):311-4. doi: 10.1089/adt.2014.1505.
9
Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation.循证数据与罕见癌症：研究与调查中一种新方法论的必要性。
Eur J Surg Oncol. 2019 Jan;45(1):22-30. doi: 10.1016/j.ejso.2018.02.015. Epub 2018 Mar 2.
10
There are other ways to manage spinal muscular atrophy type 1.
Chest. 2005 Apr;127(4):1463; author reply 1463-4. doi: 10.1378/chest.127.4.1463.
引用本文的文献
1
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.发育药理学的现有知识、挑战与创新：连接儿童专家小组和欧洲发育、围产期和儿科药理学学会白皮书。
Br J Clin Pharmacol. 2022 Dec;88(12):4965-4984. doi: 10.1111/bcp.14958. Epub 2021 Jul 23.
2
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.欧洲关于脊髓性肌萎缩症基因替代治疗的特别共识声明。
Eur J Paediatr Neurol. 2020 Sep;28:38-43. doi: 10.1016/j.ejpn.2020.07.001. Epub 2020 Jul 9.
3
Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington's Disease.罕见病标准化数据结构：Duchenne 肌营养不良症和亨廷顿病的 CDISC 用户指南。
Clin Transl Sci. 2021 Jan;14(1):214-221. doi: 10.1111/cts.12845. Epub 2020 Aug 25.
4
Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.依地酸钙钠治疗Wilson 病的经济学评价：基于中国人群的 Markov 模型研究
J Pediatr. 2020 Dec;227:274-280.e2. doi: 10.1016/j.jpeds.2020.07.033. Epub 2020 Jul 11.
5
A National Spinal Muscular Atrophy Registry for Real-World Evidence.全国性脊肌萎缩症注册登记研究真实世界证据。
Can J Neurol Sci. 2020 Nov;47(6):810-815. doi: 10.1017/cjn.2020.111. Epub 2020 Jun 4.
6
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care.脊髓性肌萎缩症治疗进展——新表型、新挑战、新护理意义。
J Neuromuscul Dis. 2020;7(1):1-13. doi: 10.3233/JND-190424.
7
SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.SMArtCARE-一个收集脊髓性肌萎缩症患者真实临床结局数据的平台。
Orphanet J Rare Dis. 2019 Jan 21;14(1):18. doi: 10.1186/s13023-019-0998-4.
8
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage.意大利神经肌肉登记处：一个协调的平台，患者组织和临床医生在此合作进行数据收集和多种用途。
Orphanet J Rare Dis. 2018 Oct 4;13(1):176. doi: 10.1186/s13023-018-0918-z.
本文引用的文献
1
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察：一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
2
Advances in therapy for spinal muscular atrophy: promises and challenges.脊髓性肌萎缩症治疗的进展：前景与挑战。
Nat Rev Neurol. 2018 Apr;14(4):214-224. doi: 10.1038/nrneurol.2018.4. Epub 2018 Feb 9.
3
Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease.自然病史、临床试验准备和基因发现：神经肌肉疾病患者登记研究的进展。
Adv Exp Med Biol. 2017;1031:97-124. doi: 10.1007/978-3-319-67144-4_5.
4
The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact.国际罕见病研究联合会：最大化影响的政策与指南。
Eur J Hum Genet. 2017 Dec;25(12):1293-1302. doi: 10.1038/s41431-017-0008-z. Epub 2017 Nov 20.
5
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
6
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.5号染色体连锁型脊髓性肌萎缩症的患病率、发病率及携带者频率——文献综述
Orphanet J Rare Dis. 2017 Jul 4;12(1):124. doi: 10.1186/s13023-017-0671-8.
7
A multi-source approach to determine SMA incidence and research ready population.一种用于确定脊髓性肌萎缩症发病率和适合研究人群的多源方法。
J Neurol. 2017 Jul;264(7):1465-1473. doi: 10.1007/s00415-017-8549-1. Epub 2017 Jun 20.
8
Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy.脊髓性肌萎缩症的诊断与新治疗途径
Neuropediatrics. 2017 Aug;48(4):273-281. doi: 10.1055/s-0037-1603517. Epub 2017 Jun 1.
9
Therapeutic approaches for spinal muscular atrophy (SMA).脊髓性肌萎缩症（SMA）的治疗方法。
Gene Ther. 2017 Sep;24(9):514-519. doi: 10.1038/gt.2017.45. Epub 2017 May 31.
10
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.奥索美那在 2 型或非卧床 3 型脊髓性肌萎缩症患者中的安全性和疗效：一项随机、双盲、安慰剂对照的 2 期临床试验。
Lancet Neurol. 2017 Jul;16(7):513-522. doi: 10.1016/S1474-4422(17)30085-6. Epub 2017 Apr 28.
Zotero 插件